ArticlePulmonary therapy2026
Peripheral Blood Inflammatory Markers and Immune Cell Profiles in Smokers With and Without COPD.
Article in Pulmonary therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCigarette smoking is a major driver of airway and systemic inflammation and contributes to the development and progression of chronic obstructive pulmonary disease (COPD). This study compared peripheral blood inflammatory markers and immune cell profiles in smokers with and without COPD and in non-smoking controls.
methodsIn this cross-sectional study, blood samples were collected from 80 participants (n = 20/group): non-smoker controls (NS), smokers with normal lung function (NLFS), current smokers with COPD (COPD-CS), and ex-smokers with COPD (COPD-ES). Total white cell count (WCC) and leukocyte differentials (neutrophils, lymphocytes, monocytes, eosinophils) were measured using an automated haematology analyser (Sysmex XN2000). Systemic inflammatory markers were measured using C-reactive protein (CRP, Roche Cobas Pro) and erythrocyte sedimentation rate (ESR, Diesse VES-MATIC Easy). Lung function parameters (including FEV1, FVC, DLco, FEF25-75%, and SpO2) were assessed and correlated with blood markers.
resultsCompared with NS, WCC, neutrophils, and monocytes were higher in both COPD groups and in NLFS (all p < 0.05). Lymphocytes were higher in NLFS and COPD-CS (p < 0.05). Eosinophils were higher in COPD-ES and NLFS relative to NS (p < 0.05). ESR and CRP were elevated in NLFS and both COPD groups compared with NS (p < 0.05). In COPD, higher blood inflammatory cell counts were associated with poorer lung function (negative correlations; p < 0.05).
conclusionPeripheral blood inflammatory markers are increased in smokers, including those with preserved lung function, and in COPD. Differences in eosinophil patterns between COPD current smokers and ex-smokers suggest inflammatory heterogeneity and should be confirmed in larger, well-characterized cohorts. These findings support the move towards careful personalized medicine interventions, based on individual inflammatory profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.